A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

852 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-06

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years of successful treatment. This high recurrence rate requires diligent and accurate monitoring as a means for early diagnosis and treatment. Considering the burden associated to repeated invasive cystoscopies, there is a need for robust but accurate tests for surveillance. In that prospect, urinary molecular tests have been developed although none were deemed adequate in the European clinical guidelines to replace cystoscopies. The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with this cancer. The test provides a fast and accurate result, is non-invasive and easy to perform. The aim of this study is to assess the non-inferiority of the Xpert Bladder Cancer Monitor assay in detecting recurrences in comparison to cystoscopy in the follow-up of patients with low or intermediate risk non-muscle-invasive bladder cancer (NMIBC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.

NCT04647981

Non-Invasive Bladder Urothelial Carcinoma Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade Non-Invasive Bladder Papillary Urothelial Carcinoma, High Grade

COMPLETED

Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

NCT03125460

Bladder Cancer

COMPLETED

Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer

NCT06751667

Bladder (Urothelial, Transitional Cell) Cancer Bladder Cancer Bladder Tumors +2 more

NOT_YET_RECRUITING NA

Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor

NCT04100733

Non-muscle Invasive Bladder Cancer Urinary Biomarker

ACTIVE_NOT_RECRUITING NA

The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor.

NCT04603612

Bladder Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patient recruitment and follow-up are closed. The study is in analysis phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-muscle-invasive Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xpert Bladder Cancer Monitor

The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient undergoing a follow-up cystoscopy at the time of enrolment for low or intermediate risk NMIBC patients in the follow-up phase (according to the 2017 EAU guidelines),
* Patient must accept to be followed for 1 year after enrolment cystoscopy,
* Patient who can provide urine samples naturally (e.g. no catheterization),
* 18 years or older at the time of enrolment,
* Signed informed consent.

Exclusion Criteria

* Patient with history of NMIBC stratified at the time of enrolment as high risk according to 2017 EAU Guidelines,
* Patient with history of Muscle-Invasive Bladder Cancer (MIBC),
* Patient having undergone a TURB less than 3 months before enrolment,
* Patient having received Mitomycin C (MMC) or Bacillus Calmette-Guerin (BCG) intravesical instillations less than 3 months before enrolment (a single MMC post-operative instillation is acceptable for inclusion).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No